Oligo Factory is opening a new oligo manufacturing facility in Holliston, MA, that will serve as the company’s new headquarters. With over 13,000 ft2 of combined bench space, offices, and labs for the company’s next generation of synthesizers, the new facility increases manufacturing capacity by 12x, explains CEO Chris Boggess.
“Oligonucleotides, or synthetic DNAs/RNAs, are used in a wide range of applications, including commercial and academic research, diagnostics for cancer or other diseases and a significant growth in RNA-based and other targeted therapeutics,” Boggess tells GEN. “The demand for the applications is growing significantly, so too does the demand for oligos. This additional capacity along with the speed and efficiency of our synthesis process will enable us to scale with our customer’s needs and market demands.”
Oligo Factory is opening its new facility after a recent growth capital investment that included Research Corporation Technologies and BroadOak Capital Partners. “The industry has a continuing need for more mid-scale production capacity,” pointed out Bill Snider, a partner at BroadOak Capital Partners.
Oligonucleotide synthesis has been an essential service to R&D in the life sciences. The use of oligonucleotides in a variety of applications, such as gene therapy, genetic testing, forensics, and basic research has led to an increase in demand for synthetic oligonucleotides.
“The fastest growing oligo sectors are nextgen sequencing, diagnostics, functional genomics/gene editing, and therapeutics,” adds Boggess.
The oligonucleotide synthesis market is projected to reach $16.7 billion by 2027 from $7.7 billion in 2022, according to report by MarketsandMarkets™. The study notes that one of the key factors driving growth is the emerging field of personalized genome sequencing. The incorporation of synthesized oligonucleotides to treat various diseases also supports market growth.
